Get started
Author

Xiuhua Weng

Observed names: X. Weng, Xiu-Hua Weng
ORCID: 0000-0001-8901-5281
Observed ORCID: 0000-0001-8901-5281
OpenAlex ID: A5031465004
A sensitive fluorescent sensor for quantification of alpha-fetoprotein based on immunosorbent assay and click chemistry
2015 · Qunfang Xie, Xiuhua Weng, et al. · Biosensors and Bioelectronics · 86
Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer
2020 · Shen Lin, Shaohong Luo, et al. · International Journal of Clinical Pharmacy · 62
Detection EGFR exon 19 status of lung cancer patients by DNA electrochemical biosensor
2016 · Xiong-Wei Xu, Xiu-Hua Weng, et al. · Biosensors and Bioelectronics · 52
First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer
2020 · Xiuhua Weng, Xiaoting Huang, et al. · American Journal of Clinical Oncology · 41
Cost‐Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels
2019 · Xiuhua Weng, Shaohong Luo, et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 32
Multimodal Ochratoxin A-Aptasensor Using 3′-FAM-Enhanced Exonuclease I Tool and Magnetic Microbead Carrier
2022 · Jin-Yuan Chen, Qing-Xia Wei, et al. · Analytical Chemistry · 25
Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion
2021 · Meiyue Li, Shen Lin, et al. · Frontiers in Oncology · 25
PDF
First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis
2021 · Shen Lin, Shaohong Luo, et al. · The Oncologist · 22
PDF
Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials
2018 · Qiuling Zhao, Ruixiang Xie, et al. · BioMed Research International · 22
PDF
First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis
2021 · Xiaoting Huang, Shen Lin, et al. · Clinical Breast Cancer · 19
DNA Nanosieve-Based Regenerative Electrochemical Biosensor Utilizing Nucleic Acid Flexibility for Accurate Allele Typing in Clinical Samples
2021 · Jin-Yuan Chen, Liang-Yong Yang, et al. · ACS Sensors · 17
Genotyping of common EGFR mutations in lung cancer patients by electrochemical biosensor
2017 · Xiu-Hua Weng, Xiong-Wei Xu, et al. · Journal of Pharmaceutical and Biomedical Analysis · 17
Cost-effectiveness analysis of genotype screening and therapeutic drug monitoring in patients with inflammatory bowel disease treated with azathioprine therapy: a Chinese healthcare perspective using real-world data
2021 · Dayong Zeng, Xiaoting Huang, et al. · Annals of Translational Medicine · 16
PDF
Electrochemical genosensor for detection of human mammaglobin in polymerase chain reaction amplification products of breast cancer patients
2013 · Xiongwei Xu, Xiuhua Weng, et al. · Analytical and Bioanalytical Chemistry · 14
Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China
2019 · Xiaoxia Wei, Hong Sun, et al. · Clinical Drug Investigation · 13
Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis
2021 · Liangliang Dong, Shen Lin, et al. · Clinical Breast Cancer · 12
Simultaneous Voltammetric Determination of Ascorbic Acid, Dopamine and Uric Acid Using Polybromothymol Blue Film-Modified Glassy Carbon Electrode
2010 · Xiongwei Xu, Qihuang Lin, et al. · Chemical and Pharmaceutical Bulletin · 12
PDF
A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma
2022 · Alan Chan, Carolyn Dang, et al. · American Journal of Clinical Oncology · 10
Disease burden of prostate cancer from 2014 to 2019 in the United States: estimation from the Global Burden of Disease Study 2019 and Medical Expenditure Panel Survey
2023 · Shen Lin, Dong Lin, et al. · Epidemiology and Health · 9
PDF
Is Olaparib Cost Effective in Metastatic Castration-Resistant Prostate Cancer Patients with at Least one Favorable Gene Mutation in BRCA1 , BRCA2 or ATM ?
2021 · Yiyuan Li, Shen Lin, et al. · Pharmacogenomics · 9
Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression
2023 · Xiaoting Huang, Dong Lin, et al. · Clinical Breast Cancer · 8
Adjuvant zoledronic acid therapy for postmenopausal women with early breast cancer in China: a cost-effectiveness analysis
2023 · Xiaoting Huang, Yiwei Liu, et al. · International Journal for Quality in Health Care · 8
Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis
2020 · Xiaoting Huang, Xiuhua Weng, et al. · BMJ Open · 8
PDF
The cost–effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma
2024 · Shufei Lai, Shaohong Luo, et al. · Pharmacogenomics · 7
PDF
Avelumab Maintenance Treatment After First-line Chemotherapy in Advanced Urothelial Carcinoma–A Cost-Effectiveness Analysis
2022 · Dong Lin, Shaohong Luo, et al. · Clinical Genitourinary Cancer · 7
Works count: 56
Citation count: 621
H-index: 14
I10-index: 18
Year
Topic
Type